课题基金 / 基金详情

Novel mechanism for UVRAG in genome stability and tumor suppression

Novel mechanism for UVRAG in genome stability and tumor suppression
UVRAG 在基因组稳定性和肿瘤抑制方面的新机制
批准号:
10221855
负责人:
Chengyu Liang
金额:
$12.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-21 至 2021-06-30

项目摘要

项目成果

Chengyu Liang的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):由于目前可用的癌症化疗和放疗的不可接受的毒性和无效,寻找新的分子靶点正在快速进行。虽然最初被确定为自噬途径的启动子,但UVRAG(抗紫外线相关基因)现在已经在我们最近的研究中作为基因组的真正守护者出现。具体来说,我们已经发现该蛋白通过靶向DNA- pk介导受损DNA的修复,并通过靶向CEP63以独立于其在自噬信号传导中的作用的方式维护中心体的稳定性。我们认为UVRAG是一种新的染色体稳定性调节因子,支持UVRAG失活在癌症发展中的直接因果作用。据我们所知,这些研究首次描述了自噬相关因子在中心体调节和DNA修复中直接起作用,以维持基因组完整性。因此,拟议的研究将扩展这一知识,全面评估UVRAG与DNA- pk相互作用以激活双链断裂(DSBs) (Aim 1)时的DNA修复(Aim 2)和靶向CEP63以防止中心体扩增(Aim 2)的分子机制,从而维持细胞的结构和数量染色体完整性。此外,为了确定染色体不稳定性和自噬在UVRAG相关肿瘤抑制中的体内贡献和特定作用(Aim 3),我们将开发一种药物诱导的转基因小鼠模型,该模型忠实地概括了在人类癌症中发现的UVRAG的致癌病变。这些目标将通过多学科的创新方法来解决,这些方法结合了最先进的遗传、生物化学、定量活细胞成像和细胞和小鼠的生理分析,这些基因突变与UVRAG相关,并且需要调节基因组稳定性和自噬。这项研究的结果无疑将阐明关于UVRAG作为自噬肿瘤抑制因子和基因组保护因子的新观点,揭示UVRAG、自噬和基因组不稳定性之间的功能相互作用,并为开发新的癌症治疗方法带来希望。
英文摘要
DESCRIPTION (provided by applicant): Due to the unacceptable toxicity and ineffectiveness of currently available cancer chemotherapy and radiation, the search for new molecular targets is in high gear. While initially identified as a promoter of the autophagy pathway, UVRAG (UV irradiation-resistance associated gene) has now emerged in our recent studies as a bona fide guardian of the genome. Specifically, we have discovered that this protein mediates the repair of damaged DNA by targeting DNA-PK and patrols centrosome stability by targeting CEP63 in a manner independent of its role in autophagy signaling. We propose that UVRAG is a novel regulator of chromosomal stability, supporting a direct causal role for UVRAG inactivation in cancer development. To the best of our knowledge, these studies represent the first description of an autophagy-related factor directly functioning in centrosome regulation and DNA repair to maintain genome integrity. Thus, the proposed research will expand on this knowledge to comprehensively assess the molecular mechanisms by which UVRAG interacts with DNA-PK to activate DNA repair upon double-strand breaks (DSBs) (Aim 1) and targets CEP63 to prevent centrosome amplification (Aim 2), thereby maintaining both structural and numeric chromosomal integrity of cells. Furthermore, to determine the in vivo contribution and specific roles of chromosomal instability and autophagy in UVRAG-associated tumor suppression (Aim 3), we will develop a drug-inducible transgenic murine model, which faithfully recapitulates an oncogenic lesion of UVRAG found in human cancers. These aims will be addressed using multidisciplinary innovative approaches that integrate state-of-the art genetic, biochemistry, quantitative live-cell imaging, and physiological assays in cells and in mice with targeted mutations in genes that are related to UVRAG and required for the regulation of genomic stability and autophagy. Results gained from this study will undoubtedly illuminate new views on UVRAG as an autophagic tumor suppressor and a protector of the genome, reveal functional interactions between UVRAG, autophagy, and genomic instability, and also hold promise for the development of novel therapeutics for cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New control of oncogene activation in T-cell leukemia
  • 批准号:
    10609073
  • 项目类别:
  • 资助金额:
    $50.42万
  • 财政年份:
    2022
  • 负责人:
    Chengyu Liang
  • 依托单位:
New control of oncogene activation in T-cell leukemia
  • 批准号:
    10443113
  • 项目类别:
  • 资助金额:
    $54.19万
  • 财政年份:
    2022
  • 负责人:
    Chengyu Liang
  • 依托单位:
Molecular Mechanism of UV Protection in Cutaneous Melanoma
  • 批准号:
    10294255
  • 项目类别:
  • 资助金额:
    $62.23万
  • 财政年份:
    2020
  • 负责人:
    Chengyu Liang
  • 依托单位:
A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC
  • 批准号:
    10264124
  • 项目类别:
  • 资助金额:
    $57.74万
  • 财政年份:
    2020
  • 负责人:
    Chengyu Liang
  • 依托单位:
国内基金
海外基金
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
  • 批准号:
    82371651
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵栋
  • 依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
  • 批准号:
    82370798
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王晓
  • 依托单位:
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
  • 批准号:
    82371332
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    胡琴
  • 依托单位: